Dr John Zebala, MD, PHD in Auburn, WA - Pathology

Dr John Zebala, MD, PHD is a Pathology - Anatomic Pathology & Clinical Pathology physician based in Auburn, Washington. Dr John Zebala is licensed to practice in Washington (license number MD00033981) and his current practice location is 215 Clay St Nw Ste B5, Auburn, Washington. He can be reached at his office (for appointments etc.) via phone at (253) 833-8009.

NPI number for Dr John Zebala is 1013634088 and his current mailing address is 3020 Issaquah Pine Lake Rd Se # 392, Sammamish, Washington. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1013634088.

Contact Information

	Dr John Zebala, MD, PHD
	215 Clay St Nw Ste B5, Auburn, WA 98001-4213
	(253) 833-8009
	Not Available

Physician's Profile

Full Name	Dr John Zebala
Gender	Male
Speciality	Pathology - Anatomic Pathology & Clinical Pathology
Location	215 Clay St Nw Ste B5, Auburn, Washington
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1013634088
Provider Enumeration Date: 10/20/2022
Last Update Date: 10/20/2022

Medical Identifiers

Medical identifiers for Dr John Zebala such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1013634088	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
207ZP0102X	Pathology - Anatomic Pathology & Clinical Pathology	MD00033981 (Washington)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Dr John Zebala is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Dr John Zebala, MD, PHD 3020 Issaquah Pine Lake Rd Se # 392, Sammamish, WA 98075-7253 Ph: (425) 466-5178	Dr John Zebala, MD, PHD 215 Clay St Nw Ste B5, Auburn, WA 98001-4213 Ph: (253) 833-8009

News Archive

Enrollment complete in Idera's IMO-3100 Phase 2 trial for psoriasis

Idera Pharmaceuticals today announced that it had completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of IMO-3100 in patients with moderate-to-severe plaque psoriasis. IMO-3100 is an antagonist of specific Toll-like Receptors (TLRs) that the Company is developing for the treatment of psoriasis and other autoimmune diseases.

Researchers explore why heart failure and kidney disease correlate

People with chronic kidney disease are at unusually high risk of also developing cardiovascular disease; in fact, a patient with non-dialysis kidney disease is more likely to die of heart failure than to develop end-stage kidney failure.

NPCs as effective as doctors in performing Caesarean sections

Every year, some 7.5 million mothers and new-borns die during pregnancy or childbirth, almost all of whom are in low and middle-income countries. One reason for this is the lack of trained medical staff, particularly doctors. A doctoral thesis from Karolinska Institutet now shows that a solution could be the training of nurses in caesarean sections and other life-saving surgery.

Savient Pharmaceuticals' total revenues reach $1.1M in first-quarter 2010

Savient Pharmaceuticals, Inc. announced that its board of directors, with input from its financial advisors, has determined that a sale of Savient post-approval of KRYSTEXXA by the U.S. Food and Drug Administration (assuming KRYSTEXXA is approved) would be the best way to realize the full commercial potential of KRYSTEXXA on a global basis and would be the optimal outcome for the Company's shareholders and other stakeholders.

Dr John Zebala, MD, PHD - Pathology in Auburn, WA